Aslan Pharmaceuticals Pte. Ltd. has raised a total of $34m in a Series C financing involving existing and new investors, which it will use mainly to progress its pipeline.
The new round takes the total raised to date by the Singapore-based, oncology-focused venture to $69m, including equity financing and funding from the Singapore government, ASLAN CEO Dr
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?